大行评级｜小摩：内地手术机器人服务定价标准化，利好微创机器人商业化前景

Group 1 - The core viewpoint of the article is that the new pricing guideline for pathological medical services issued by China's National Healthcare Security Administration will have a structurally positive impact on the surgical robot market in China [1] - The guideline establishes a consistent pricing path and promotes a shift towards value-oriented and tiered reimbursement models in the industry [1] - This initiative is expected to support broader clinical applications of surgical robots and encourage the research and use of advanced surgical robots [1] Group 2 - Market reaction to the news was notably positive, with the stock price of MicroPort Robotics rising approximately 15% following the announcement, indicating increased visibility of the reimbursement mechanism and a clearer commercialization path [1] - Morgan Stanley has given MicroPort Robotics an "Overweight" rating with a target price of 42 HKD [1]